BP
WST icon

Ballentine Partners’s West Pharmaceutical WST Stock Holding History

Ballentine Partners’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,346
Closed -$301K – 1073
2025
Q1 		$301K Buy
1,346
+445
+49% +$123K 0.01% 626
2024
Q4 		$295K Buy
901
+135
+18% +$42.5K 0.01% 596
2024
Q3 		$230K Buy
766
+24
+3% +$7.35K ﹤0.01% 699
2024
Q2 		$244K Buy
742
+33
+5% +$11.7K ﹤0.01% 621
2024
Q1 		$281K Sell
709
-31
-4% -$11.5K 0.01% 553
2023
Q4 		$261K Sell
740
-193
-21% -$68.3K 0.01% 546
2023
Q3 		$350K Buy
933
+19
+2% +$7.35K 0.01% 400
2023
Q2 		$350K Sell
914
-1
-0.1% -$357 0.01% 409
2023
Q1 		$317K Buy
+915
New +$267K 0.01% 403
2022
Q2 		– Sell
-658
Closed -$270K – 490
2022
Q1 		$270K Buy
658
+158
+32% +$61.9K 0.01% 373
2021
Q4 		$235K Buy
+500
New +$215K 0.01% 416

Other funds holding WST

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
APG Asset Management
APG Asset Management Amsterdam, Netherlands $40.7B AUM 39.97% 1-Year Est. Return

Ballentine Partners's WST Position: Q2 2025 in Review

Ballentine Partners sold out of West Pharmaceutical (WST) in Q2 2025, closing a stake of 1,346 shares — an estimated $301K sold.

Ballentine Partners first reported a position in WST in Q4 2021 and held it in 11 quarters. The position peaked at $350K in Q3 2023. 730 funds tracked by Wall St. Rank hold WST as of Q2 2025.

  • Ballentine Partners reported no remaining West Pharmaceutical position as of Q2 2025 after selling out during the quarter.
  • Ballentine Partners sold 1,346 West Pharmaceutical shares in Q2 2025, an estimated $301K.
  • Ballentine Partners first reported a position in West Pharmaceutical in Q4 2021 and held it in 11 quarters.
  • Ballentine Partners's West Pharmaceutical position peaked at $350K in Q3 2023.
  • 730 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2025.

Based on Ballentine Partners's 13F filing for Q2 2025, filed 15 Jul 2025.